EcoDrugPlus

60s Ribosomal Protein L7

Ensembl ID : ENSCING00000007209
Gene Symbol: LOC101242128
4 Cross references
817 Possible Orthologues:

60s Ribosomal Protein L7a

Ensembl ID : ENSCING00000009395
Gene Symbol: LOC100186345
4 Cross references
373 Possible Orthologues:

60s Ribosomal Protein L8

Ensembl ID : ENSCING00000023083
Gene Symbol: LOC100185367
4 Cross references
282 Possible Orthologues:

60s Ribosomal Protein L9

Ensembl ID : ENSCING00000009310
Gene Symbol: LOC100177652
4 Cross references
516 Possible Orthologues:

G Protein-Activated Inward Rectifier Potassium Channel 4

Ensembl ID : ENSCING00000023776
Gene Symbol: LOC100180954
4 Cross references
1156 Possible Orthologues:

Alpha-N-Acetylgalactosaminidase-Like

Ensembl ID : ENSCING00000019677
Gene Symbol: LOC100182270
4 Cross references
445 Possible Orthologues:

Atrial Natriuretic Peptide Receptor 1

Ensembl ID : ENSCING00000001143
Gene Symbol: LOC100177156
3 Cross references
187 Possible Orthologues:

Atrial Natriuretic Peptide Receptor 3-Like

Ensembl ID : ENSCING00000021958
Gene Symbol: LOC100178228
4 Cross references
212 Possible Orthologues:

Cannabinoid Receptor

Ensembl ID : ENSCING00000007801
Gene Symbol: CIAD70L24
4 Cross references
1281 Possible Orthologues:

Casein Kinase 2 Alpha Subunit

Ensembl ID : ENSCING00000009515
Gene Symbol: CK2A
4 Cross references
625 Possible Orthologues:

Cholecystokinin Receptor Type A-Like

Ensembl ID : ENSCING00000005928
Gene Symbol: LOC100181046
4 Cross references
462 Possible Orthologues:

Cholinesterase-Like

Ensembl ID : ENSCING00000016954
Gene Symbol: LOC100186611
4 Cross references
312 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).